Aranesp coverage decision
Executive Summary
D.C. federal court dismisses Amgen's challenge of the Centers for Medicare & Medicaid Services' decision to reimburse Aranesp (darbepoetin) at the same level as Johnson & Johnson's Procrit (epoetin) under the final Hospital Outpatient Prospective Payment System rule for 2003. In a Dec. 26 1opinion, the court determined that Amgen lacked standing to challenge CMS from implementing certain provisions relating to Aranesp. CMS concluded that the two anemia therapies are "functionally equivalent" (2"The Pink Sheet" Nov. 4, p. 27)...
You may also be interested in...
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: